title: The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer.
abstract: BACKGROUND
  It has been proved that hepatitis B virus (HBV) infection alters the metastatic pattern and affects survival in colorectal cancer (CRC) and hepatocellular carcinoma (HCC), while the influence of HBV infection on metastatic pattern and survival in patients with pancreatic cancer (PC) has not been investigated yet.
  
  
  METHODS
  We conducted an investigation to evaluate the impact of HBV infection on metastatic pattern and overall survival in PC. We collected the data of 460 PC patients treated in our hospital from 1999 to 2010. Serum HBV markers were tested with enzyme-linked immunosorbent assay. The impact of HBV infection on metastatic pattern and overall survival was analyzed.
  
  
  RESULTS
  We found that the incidence of synchronous liver metastasis was significantly higher in patients with HBsAg positive than those with HBsAg negative (46.0% vs 32.0%, P < 0.05), and higher in chronic HBV infection (CHB) group than both non HBV infection and resolved HBV infection group (61.1% vs 33.9%, P < 0.05, and 61.1% vs 28.7%, P < 0.05, respectively). What's more, Kaplan-Meier analysis showed that CHB, resolved HBV infection and non HBV infection group had significant longer overall survival (OS) compared with inactive HBsAg carriers (IC) group (P=0.037, P=0.009, and P=0.019 respectively). But, in the multivariate analysis, only the CHB and non HBV infection group had significant better overall survival compared with IC group (P=0.010 and P=0.018 respectively).
  
  
  CONCLUSIONS
  Our study found that HBV infection increased synchronous liver metastasis rate, and HBV infection status was an independent prognostic factor in PC patients.
authors.affiliation: State Key Laboratory of Oncology in South China, Department of Medical Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. xurh@sysucc.org.cn.
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Wei
authors.forename: Miao-zhen
authors.initials: MZ
authors.lastname: Qiu
authors.forename: Wei-wei
authors.initials: WW
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Jin
authors.forename: Chao
authors.initials: C
authors.lastname: Ren
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.forename: Hui-yan
authors.initials: HY
authors.lastname: Luo
authors.forename: Zhi-qiang
authors.initials: ZQ
authors.lastname: Wang
authors.forename: Dong-sheng
authors.initials: DS
authors.lastname: Zhang
authors.forename: Feng-hua
authors.initials: FH
authors.lastname: Wang
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Li
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Xu
mesh_terms: D044466:Asian People; D002681:China; D005260:Female; D005500:Follow-Up Studies; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000276:immunology / Q000821:virology*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000276:immunology / Q000473:pathology* / Q000821:virology; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D006514:Hepatitis B Surface Antigens